BÜHLMANN fCAL® ELISA Archives - Buhlmann Diagnostics Corp

Tag: BÜHLMANN fCAL® ELISA

Visit BUHLMANN @ AMLI 2024 (LIVE)

AMLI 2024 Assay Offering: BUHLMANN is proud to partner with this event. We offer a comprehensive Immunology assay product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications. Visit www.buhlmannlabs.com or email info@buhlmannlabs.com for more information.   AMLI 2024 37th AMLI Annual Meeting Aug 16-19,
Continue Reading

Visit BUHLMANN @ AMLI 2023 (LIVE)

AMLI 2023 Assay Offering: BUHLMANN is proud to partner with this event. We offer a comprehensive Immunology assay product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications. Visit www.buhlmannlabs.com or email info@buhlmannlabs.com for more information.   AMLI 2023 36th AMLI Annual Meeting Aug 11-14,
Continue Reading

Faecal Calprotectin Predicts Endoscopic and Histological Activity

BÜHLMANN fCAL® ELISA Citation Lara Hart et al. Faecal Calprotectin Predicts Endoscopic and Histological Activity in Clinically Quiescent Ulcerative Colitis, Journal of Crohn's and Colitis, Volume 14, Issue 1, January 2020, DOI: doi.org/10.1093/ecco-jcc/jjz107 READ CITATION BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use. Health Canada License: 80726 This citation describes applications that are outside of
Continue Reading

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al.  The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study.  Crohn's & Colitis 360 (2019).  DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”
Continue Reading

Check Us Out at AMLI 2019

We offer a comprehensive autoimmunity product line comprised of robust assays for simple, esoteric testing for important markers and it is supported by numerous publications.  Anti-MAG Autoantibodies ELISA  US: Research Use Only.  Not for use in diagnostic procedures. Canada: Health Canada License: 89118 This assay is intended for the quantitative determination of human IgM-auto-antibodies directed
Continue Reading

Visit BUHLMANN at AACC 2019

 Assays Offerings: We offer a selection of unique, high-quality assays for Cellular Allergy testing such as the BÜHLMANN Flow CAST® product group  and numerous Allergens for Basophil Activation Testing and Neuroimmunology testing such as the BÜHLMANN GanglioCombi® products; the only screening ELISAs for anti-Ganglioside testing and Anti-MAG Autoantibodies ELISA. Other areas of BÜHLMANN’s focus include specialized niche products for Clinical Chemistry (ACE, GHB, etc.) as well
Continue Reading

Educational Webinar- Calprotectin in the Diagnosis of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease.

BÜHLMANN fCAL® ELISA Citation Pavlidis, P. et al., 2016, Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease, Scandinavian Journal of Gastroenterology.  PMID: 27400728  DOI: 10.1080/00365521.2016.1205128 Highlight from this Publication “The ΔFCAL could act as an ‘early warning’ to consider alternatives such as dose optimisation or another biologic with a different mode of action,
Continue Reading